Overview

* Aptar Q3 sales increase 6%, beating analyst expectations

* Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

* Company returned $70 mln to shareholders via buybacks and dividends

Outlook

* Aptar expects Q4 2025 adjusted EPS between $1.20 and $1.28

* Company anticipates strong Pharma segment growth, driven by GLP-1 and biologics demand

* Aptar foresees less favorable sales mix due to lower emergency-use system sales

Result Drivers

* PHARMA GROWTH - Strong product volume growth in Pharma, especially in injectables, drove sales increase

* BEAUTY SEGMENT - Beauty segment sales increased due to currency and acquisitions, but core sales remained flat

* CLOSURES CHALLENGES - Closures segment faced lower tooling sales and resin pricing, affecting core sales

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $961 mln $953.50

mln (6

Analysts

)

Q3 Beat $1.62 $1.56 (7

Adjusted Analysts

EPS )

Q3 EPS $1.92

Q3 Net $128 mln

Income

Q3 Beat $223 mln $212.98

Adjusted mln (6

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

* Wall Street's median 12-month price target for Aptargroup Inc ( ATR ) is $167.00, about 25.5% above its October 30 closing price of $124.36

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)